Safety and Proof of Principle Study of ATX-GD-59 in Male and Female Subjects With Graves' Disease Not Currently Treated With Anti-thyroid Therapy: An Open Label Study, With an Upward Titration Over Five Dose Levels Administered by Intradermal Injection.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Sep 2017
At a glance
- Drugs ATX-GD 59 (Primary)
- Indications Graves' disease
- Focus Adverse reactions
- Sponsors Apitope Technology
- 05 Sep 2017 Planned End Date changed from 1 Oct 2017 to 1 Dec 2017.
- 05 Sep 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
- 03 Jul 2017 Status changed from recruiting to active, no longer recruiting.